The Noramco Group, an integrated North American-based API and drug product supply chain product and services provider, announced a $25 million investment in its Halo Pharma facility in Whippany, New Jersey, to establish sterile injectable manufacturing capabilities, including ready-to-use syringe, cartridge, and vial filling. This expansion aims to address critical capacity shortages in the US injectable supply chain and meet the growing demand from pharmaceutical companies seeking reliable domestic sterile manufacturing partners.
With sterile injectables representing the fastest-growing segment of the pharmaceutical market, demand for commercial and clinical-scale capacity continues to outpace available supply. Many injectable products remain on the FDA’s drug shortage list, exacerbated by the surge in demand for biologics and by the critical needs of the U.S. hospital supply chain. The Noramco Group’s investment will provide branded and generic pharmaceutical companies with a North American-based solution for sterile injectable manufacturing, strengthening the domestic production of critical drugs and reinforcing supply chain security and reliability.
“This investment is a significant step in our commitment to build on our position as one of the only fully integrated domestic supply options for our customers,” said Lee Karras, CEO of The Noramco Group. “We recognize the challenges facing the industry and are dedicated to providing solutions that address both immediate and long-term supply chain needs. We anticipate the new line to be qualified and operational within the next 12 months, ensuring we can support customers with the high-quality capacity they require. While this investment enhances our capabilities with contemporary technologies, with the addition of sterile manufacturing we remain committed to our already established and proven focus on manufacturing APIs, oral solid dose, and liquid dosage forms, which continue to be essential in meeting our customers’ needs.”
Comments powered by CComment